Combination Therapy

Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab

Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab

[Cancer Management and Research] The research examines the various combination strategies for the treatment of multiple myeloma, with a focus on the use of elotuzumab.

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

By

Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

By

Twice daily radiation therapy with chemotherapy may improve survival times in patients with some advanced head and neck cancers, a new study confirms.

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

By

Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

By

Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.

Continued Enzalutamide Strategy Fails to Benefit mCRPC

Continued Enzalutamide Strategy Fails to Benefit mCRPC

By

Men who had PSA progression on enzalutamide but continued on the drug did not have improved PFS when abiraterone was added to their therapy.

IL-11 Plus Glucocorticoids Safe, Effective for ITP in Adults

IL-11 Plus Glucocorticoids Safe, Effective for ITP in Adults

By

Recent study results demonstrate that recombinant IL-11 with glucocorticoids is a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP) in adults.

Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

By

Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.

Multimodal Strategy Shows Promise in Metastatic Prostate Cancer

Multimodal Strategy Shows Promise in Metastatic Prostate Cancer

By

New paradigm of hormone therapy, surgery, and radiation therapy was shown effective at achieving undetectable disease in patients with metastatic prostate cancer.

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

By

Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.

AntiCancer, Rheumatoid Arthritis Drug Combination Produced Synergistic Attack on Tumor Cells

AntiCancer, Rheumatoid Arthritis Drug Combination Produced Synergistic Attack on Tumor Cells

By

The combination of an anticancer agent with a rheumatoid arthritis medication results in synergistic effect that improves the efficacy of the anticancer agent.

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

By

Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.

Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly

Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly

By

The addition of temozolomide to short-course radiotherapy in elderly patients with glioblastoma was associated with some survival benefit compared with radiotherapy alone.

Single Chemotherapy Dose Informs Treatment Strategy for Advanced Laryngeal Cancer

Single Chemotherapy Dose Informs Treatment Strategy for Advanced Laryngeal Cancer

By

A new approach in which patients receive a single dose of chemotherapy may greatly improve the laryngeal cancer survival rate.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

By

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

By

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

By

Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

Topical Combination Reduces Actinic Keratosis Lesions, Reducing Risk of Squamous Cell Carcinoma

Topical Combination Reduces Actinic Keratosis Lesions, Reducing Risk of Squamous Cell Carcinoma

By

Study investigates the effectiveness of a topical treatment with an immune system-activator and a topical chemotherapy on actinic keratosis, a precursor to squamous cell carcinoma.

BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

By

The combination of bendamustine, lenalidomide, and dexamethasone was highly active as second-line treatment for relapsed/refractory multiple myeloma.

Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas

By

In a phase 1 clinical trial, the combination produces a significant and long-lasting response in patients with advanced disease including metastases to the peritoneum and lung.

Panobinostat, Bortezomib, Thalidomide Efficacious in Relapsed Myeloma

By

In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.

Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma

By

The US FDA granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin for the treatment of certain patients with soft tissue sarcoma.

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

By

Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC

By

The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

By

Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

By

The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).

Chemoradiation Combination Could Preserve Larynx in Patients With Laryngeal and Hypolaryngeal Cancer

Chemoradiation Combination Could Preserve Larynx in Patients With Laryngeal and Hypolaryngeal Cancer

By

Researchers assessed the rates of laryngeal preservation and laryngectomy-free survival in patients with laryngeal or hypopharyngeal cancer who received the monoclonal antibody cetuximab and radiation therapy or radiation therapy alone.

Immunotherapy Combination is Effective in Colorectal Cancer

By

Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).

Novel Nanoparticle Achieves Concomitant Tumor Cell Death and Resistance Suppression

By

Resistance to therapy through adaptation poses a major hurdle for cancer therapy. Bioengineers addressed this by creating a single nanoparticle that comprises a synergistic drug pair that shuts down mechanisms of resistance to a degree that has not been previously achieved.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs